{"id":"W3049330696","doi":"10.1158/1538-7445.am2020-ct302","title":"Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"TIGIT; Atezolizumab; Medicine; Tolerability; Oncology; Pharmacodynamics; Antibody; Internal medicine; Pharmacokinetics; Pharmacology; Cancer; Immunotherapy; Immunology; Adverse effect; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002640661,0.0001290415,0.0002898881,0.0001808301,0.00007368818,0.00002772113,0.0001144157,0.00004212024,0.00004867797],"category_scores_gemma":[0.00004875382,0.00008472198,0.00002170612,0.0009978373,0.0001763599,0.000129324,0.00004655115,0.0003180166,0.000001126169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000307216,"about_ca_system_score_gemma":0.0002798255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001213023,"about_ca_topic_score_gemma":0.0006694372,"domain_scores_codex":[0.998224,0.0001069506,0.0003090349,0.0003236331,0.0007623947,0.0002740484],"domain_scores_gemma":[0.9993219,0.00004324864,0.0001184303,0.0002160617,0.0002210792,0.00007926721],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0439605,0.004851563,0.8190553,0.0002955797,0.0001129995,0.00005741587,0.006194457,0.0002288686,0.07092463,0.000003042917,0.00003674998,0.05427884],"study_design_scores_gemma":[0.03655617,0.006912069,0.9453232,0.0006995643,0.00001349496,0.000001452605,0.001250255,0.0001140911,0.00897637,0.000005198541,0.00004591214,0.0001021824],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968371,0.00020665,0.000001610332,0.0006061069,0.00002556726,0.002159648,0.00001046179,0.00001066985,0.0001421942],"genre_scores_gemma":[0.9997031,0.00007233834,0.000006918256,0.00006296263,0.00001538341,0.00007652799,0.00002005219,0.00002325646,0.00001942545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1262679,"threshold_uncertainty_score":0.3454862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04779853249571873,"score_gpt":0.4007939234105441,"score_spread":0.3529953909148253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}